{
  "data": {
    "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGD9",
    "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGD9",
    "indicator": {
      "slug": "countries-with-drug-approval",
      "name": "Countries with drug approval",
      "definition": "Number of countries in which a medicine has been granted regulatory approval for a given indication."
    },
    "industry": [
      {
        "slug": "pharmaceuticals",
        "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
        "isic": "C21",
        "is_primary": true
      }
    ],
    "region": {
      "code": "GLOBAL",
      "name": "Global",
      "type": "world"
    },
    "period": {
      "start": "2026-09-10",
      "end": "2026-09-10",
      "type": "point"
    },
    "value": 90,
    "value_text": "approximately 90 countries",
    "unit": "count",
    "currency": null,
    "scale": "1",
    "value_type": "actual",
    "source": {
      "org": "Roche",
      "org_short_name": "Roche",
      "org_url": "https://www.roche.com",
      "org_tier": 2,
      "document_title": "U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments",
      "document_url": "https://www.roche.com/media/releases/med-cor-2026-09-10",
      "document_type": "press_release",
      "locator": "About Enspryng (satralizumab)",
      "quote": "Enspryng is the first and only IL-6 inhibitor treatment currently approved in approximately 90 countries for neuromyelitis optica spectrum disorder (NMOSD), including in the U.S. and E.U., with a well-established safety profile in over 10,000 patients.",
      "published_date": "2026-09-10",
      "accessed_at": "2026-09-15",
      "license": "see-source",
      "url_status": "ok"
    },
    "verification": "verified",
    "verified_by": "seed:auto-extract-v1",
    "verified_at": "2026-09-15T22:15:46.809Z",
    "confidence": 0.9,
    "is_secondhand": false,
    "supersedes": null,
    "superseded_by": null,
    "is_current": true,
    "citation": {
      "apa": "Roche. (2026). U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments. Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-09-10. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGD9",
      "bibtex": "@misc{roche2026countriesbjmgd9,\n  author       = {{Roche}},\n  title        = {U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments},\n  year         = {2026},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGD9},\n  note         = {Original source: https://www.roche.com/media/releases/med-cor-2026-09-10. Accessed September 15, 2026.}\n}"
    },
    "updated_at": "2026-09-15T22:15:46.809Z",
    "contested_by": [],
    "related": []
  },
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 1
  }
}